Cantor Fitzgerald Assumes Longboard Pharmaceuticals at Overweight, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has assumed Longboard Pharmaceuticals (NASDAQ:LBPH) with an Overweight rating and raised the price target to $35.
October 24, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals' stock has been given an Overweight rating by Cantor Fitzgerald, with a raised price target of $35.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Longboard Pharmaceuticals. The raised price target to $35 suggests that the analyst expects the stock to outperform in the short term. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100